PMID: 8993522Dec 13, 1996Paper

CPT-11. The European experience

Annals of the New York Academy of Sciences
J P ArmandO Rixe

Abstract

CPT-11 is a derivative of camptothecin, which has a broad spectrum of antitumor activity, both in vitro and in vivo. Like camptothecin, CPT-11 is a selective inhibitor of the DNA enzyme topoisomerase I. Phase I trials were conducted in Europe with the aim of determining the recommended CPT-11 dose and schedule for evaluation in phase II trials. The phase I trials assessed the toxicity of CPT-11 in 235 patients and tested three different administration schedules. CPT-11 was administered as a single infusion once every three weeks, as a weekly infusion for three weeks out of every four, and as a daily infusion for three consecutive days every three weeks. The maximum tolerated dose (MTD) was 115 mg/m2 in the daily schedule and 145 mg/m2 in the weekly schedule. When the drug was administered once every three weeks, diarrhea became the dose-limiting toxicity at doses above 350 mg/m2. This schedule allowed the highest dose intensity to be obtained, was the best tolerated, and allowed ambulant treatment. Finally, using this schedule, a combination of CPT-11 with high doses of loperamide allowed the dose of CPT-11 to be increased to 750 mg/m2. An ongoing phase I trial is investigating the combination of CPT-11 and 5-fluorouracil (5-FU...Continue Reading

References

Jan 1, 1991·Cancer Chemotherapy and Pharmacology·Y KawatoK Matsumoto
May 1, 1980·Journal of Medicinal Chemistry·M C WaniM E Wall
Jul 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P ArmandP Rougier
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E GonçalvesJ P Armand
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·F LokiecA Mathieu-Boué
Feb 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J WagenerJ Verweij
Feb 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CatimelM Clavel
Feb 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G G ChabotR Bugat
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D AbigergesD Gandia
Mar 16, 1994·Journal of the National Cancer Institute·D AbigergesD Gandia
Jan 1, 1994·Cancer Treatment Reviews·G J CreemersJ Verweij
Jan 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D GandiaP Herait

❮ Previous
Next ❯

Citations

Nov 13, 2003·British Journal of Cancer·C MarkhamA B Hassan
Sep 10, 2003·Journal of Chemotherapy·W T LimW H Koo
Nov 6, 2002·Journal of Experimental Therapeutics & Oncology·Hiroaki SatohKiyohisa Sekizawa
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J O'Leary, F M Muggia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.